Loading...
Working together for the family: determination of HER oncogene co-amplifications in breast cancer
HER2 is a well-studied tyrosine kinase (TK) membrane receptor which functions as a therapeutic target in invasive ductal breast carcinomas (IDC). The standard of care for the treatment of HER2-positive breast is the antibody trastuzumab. Despite specific treatment unfortunately, 20% of primary and 7...
Saved in:
| Published in: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Impact Journals LLC
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7367656/ https://ncbi.nlm.nih.gov/pubmed/32733648 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27671 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|